Trials / Completed
CompletedNCT00688753
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAD001 |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2008-06-03
- Last updated
- 2016-09-02
- Results posted
- 2015-11-26
Locations
19 sites across 6 countries: Belgium, France, Germany, Italy, Poland, Spain
Source: ClinicalTrials.gov record NCT00688753. Inclusion in this directory is not an endorsement.